Summary of NovaBay Pharmaceuticals 2026 Special Meeting Company Overview - Company Name: NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) - Meeting Date: March 12, 2026 - Meeting Type: Special Meeting of Stockholders Key Points Discussed Meeting Structure - The meeting was presided over by Michael Kazley, CEO and Chairman of the Board, with other board members and guests participating virtually [2][3] - The meeting included a formal session to address official business and a subsequent informal Q&A session [4] Voting Proposals 1. Private Placement Issuance Proposal - Approval for the issuance of 837,696,130 shares of common stock upon exercise of pre-funded warrants from the January 2026 private placement [9] - The board recommended approval [11] 2. October Warrant Share Issuance Proposal - Approval for the issuance of 5,405,406 shares of common stock upon exercise of pre-funded warrants from October 2025 [12] - The board recommended approval [14] 3. Written Consent Proposal - Amendment to the certificate of incorporation to permit stockholder action by written consent [15] - The board recommended approval [16] 4. Officer Exculpation Proposal - Amendment to provide for officer exculpation under Delaware law [17] - The board recommended approval [18] 5. Authorized Common Stock Proposal - Increase the number of authorized shares of common stock from 1.5 billion to 5.0 billion [19] - The board recommended approval [20] 6. Equity Incentive Plan Proposal - Approval of the 2026 equity incentive plan [22] - The board recommended approval [22] Voting Results - A quorum was established with approximately 96.73% of voting power represented [7] - All six proposals were approved by stockholders [24] Additional Important Information - The record date for stockholders entitled to vote was February 10, 2026 [5] - The meeting included a formal voting process where stockholders could vote in person or by proxy [11][20] - The meeting concluded with an invitation for questions from stockholders, indicating a focus on transparency and engagement [25]
Novabay Pharmaceuticals (NYSEAM:NBY) 2026 Extraordinary General Meeting Transcript